| INTRODUCTION
Candida species are among the leading causes of invasive fungal disease worldwide and are one of the most common hospital-acquired bloodstream infections.
1 Such infections are associated with substantial morbidity and mortality as well as increased healthcare costs. 2 In some countries, Candida parapsilosis is the second most commonly isolated Candida species from blood cultures after C. albicans. 3 The Infectious Diseases Society of America update of the treatment guideline for candidiasis recommends the empiric use of an echinocandin. 4 A recent study supports the recommendations: in 307 patients with C. parapsilosis candidaemia there was no difference in 30-day mortality between patients receiving an echinocandin or fluconazole.
5
In patients with a history of prior treatment with an echinocandin, and those with C. parapsilosis infection, testing for echinocandin susceptibility is suggested, as breakthrough C. parapsilosis infections during echinocandin treatment have been observed.
6
Anidulafungin is an agent of the echinocandin class that has been approved in Europe and the United States for the treatment of candidaemia and other forms of invasive candidiasis. When compared with other Candida species, C. parapsilosis exhibits higher in vitro minimum
| Treatments
Patients received a 200 mg loading dose of intravenous (IV) anidulafungin on day 1 followed by 100 mg daily thereafter. In all studies except study A8851022 (NCT00805740), investigators had the option to switch to an oral azole (fluconazole or voriconazole) after ≥5 or ≥10 days of treatment with anidulafungin based on prespecified criteria.
| Efficacy endpoints
The purpose of the current analysis was to determine the effi- 
| Safety and tolerability endpoints
The ITT population (all patients who received ≥1 dose of anidulafungin)
was used for the safety analysis (secondary endpoint). Serious adverse events and the incidence and severity of treatment-emergent adverse events of all causalities were summarised by Medical Dictionary for Regulatory Activities (MedDRA) preferred term.
| Statistical analyses
This was an analysis in estimation and no hypotheses for efficacy endpoints were tested. Evaluation consisted of descriptive statistics.
Success rates for global response were estimated with exact 95% confidence intervals (CI) for binomial proportion (Clopper-Pearson method). In efficacy analyses, indeterminate or missing data were considered failures.
| RESULTS
Seventy patients with culture-confirmed candidaemia caused by C. parapsilosis at baseline were identified in the database (modified ITT population). Ten of these patients were co-infected with other Candida baseline pathogens including five C. glabrata, three C. albicans, one C. norvegensis and one C. tropicalis. Baseline patient characteristics for this group are shown in Table 1 . The majority of patients were male and white. The mean age was 54.9 years. Acute Physiology and Chronic Health Evaluation II (APACHE II) score was collected in 69 patients who had a mean baseline score of 13.1.
Twenty-seven patients had a score ≥15. Haematological malignancies were present in 10% of patients (7/70) and 18.6% of patients had solid tumours (13/70).
The most common risk factors (occurring in ≥50% of patients)
for candidaemia were use of broad spectrum antibiotics and central venous catheters ( Table S1 . Table 3 .
| Efficacy

| Safety and tolerability
Out of a total of 70 evaluable patients, 24 experienced serious adverse events and 58 experienced treatment-emergent adverse events, with infections and infestations being the most commonly reported
MedDRA adverse event category. Most adverse events were mild or moderate in severity. No new anidulafungin safety concerns were identified in this analysis.
| DISCUSSION
To the best of our knowledge, this pooled analysis of six prospective studies comprising 70 patients is the largest clinical experience of the use of anidulafungin in fungaemia caused by C. parapsilosis.
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